BRAF and sarcoma: To assess whether the sarcoma cell lines with a poor or short-term effect on cell growth circumvent the need for BRAF to be able to phosphorylate ERK, we evaluated the levels of p-ERK protein following treatment with vemurafenib for 3 or 72 h.